A Study of Pulmonary Vascular Disease Phenomics Program

Overview

About this study

The purpose of this study is to retest participants at a minimum 6 month interval from initial evaluation using a core set of clinical and OMICS features. This will include survival, clinical staging, clinical group assignment, 6-minute walk, echocardiography, and blood for a broad collection of selected OMICS tests, to include proteomics and other variables found to be informative in the initial set.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Only participants who completed the parent PVDOMICS study will be approached for the L-PVDOMICS Study.  This includes all participants:
    • PH, comparators and controls with a minimum 6 months post-enrollment in PVDOMICS. 
  • See the parent PVDOMICS protocol for full details of inclusion/exclusion criteria.
  • Any PH, comparators or control participant previously enrolled in the parent PVDOMICS protocol with a minimum of six months post-enrollment.
  • Dialysis dependent renal function since the parent study acceptable.

Exclusion Criteria:

Participant Level 1

  • Previously received a heart and/or lung transplant
  • In the clinician’s opinion, too ill to perform L-PVDOMICS testing even if limited testing.
  • Participants who withdrew from the parent PVDOMICS study.
  • Pregnant or nursing.
  • Concurrent participation in any pulmonary hypertensioninvestigational drug study or other blinded placebo-controlled drug clinical trial.

Participant Level 2:  

  • Transplant other than heart or lung.
  • Participants who withdrew from the parent PVDOMICS study.

Participant Level 3:  

  • Participants who withdrew from the parent PVDOMICS study.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Robert Frantz, M.D.

Closed for enrollment

Contact information:

Robert Frantz M.D.

(507) 538-1262

frantz.robert@mayo.edu

More information

Publications

Publications are currently not available